Immunologic mechanisms of EPO-associated pure red cell aplasia.
about
Current status of biosimilars in the treatment of inflammatory bowel diseasesIs extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administrationQuality of original and biosimilar epoetin productsImprovement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG-PLA micelle.Factors of importance for a successful delivery system for proteins.Oxygen delivery enhancers: past, present, and future.Biosimilars: current status and future directions.Immunogenicity of therapeutic proteins: the use of animal models.Clinical safety of biosimilar recombinant human erythropoietins.Epoetin biosimilars in Europe: five years on.Clinical development of biosimilars: an evolving landscape.Preclinical models used for immunogenicity prediction of therapeutic proteins.Biosimilars advancements: Moving on to the future.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.Willingness to pay for adverse drug event regulatory actions.Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.Nanoparticulate Impurities in Pharmaceutical-Grade Sugars and their Interference with Light Scattering-Based Analysis of Protein Formulations.Biosimilar therapeutics-what do we need to consider?Anti-epoetin-antibody-induced anemia in a child with chronic renal failure.Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia.
P2860
Q26765350-CA8D148C-1112-4B9B-86C8-53285DF2CAB3Q30675199-81D8F1E7-A763-416D-B9AF-55C3D5607C31Q34064079-24AC3585-44F0-44EE-A91C-19716CD69B01Q34519785-F22ED38D-0B32-4770-A37C-756A3996227EQ36142527-B719AE37-3E71-4B03-85CB-CC46D86A2E0CQ36316926-97A0BEB4-621A-465B-B3DF-8989CEDFE734Q37117367-1C10E88D-229B-49DE-8D33-0F9CD0E91223Q37729154-F3B49FA1-36FB-41DE-A3DE-4AE6DA950C13Q37899800-7F8BDB02-3556-4FF9-A91A-655816D89EF0Q38033576-995C3AA8-3667-404B-8F6B-C5D2D59DACDDQ38067654-E7761BDD-4ED7-454B-B9B6-9A9A045FE5EBQ38083094-8CBBC9EA-5BB1-40B7-AEA5-59F188A6F7DBQ38104674-57BB71BF-17DF-4012-8239-C8D923D965D6Q38364577-5A98F4E1-D037-4852-A3FB-495362B34BC7Q38708927-0AB2E524-15F8-47C4-A72C-41286F36BD65Q38786144-FE37C697-DCD0-41A3-8883-FFE3C8B4B11FQ39708473-CAC491D5-693B-4343-A91F-68D58F17FFD8Q40939952-57B49C0F-CC2A-49FE-8F48-E17E013E2E41Q41558985-D56EDC0F-C7F2-49FF-BE9D-88AB3FDC5834Q41841849-C37C8AF7-9978-47F3-BE9D-ECE42F1141FFQ42870448-84766259-9998-4260-A899-8A4FA8470780Q50654749-84ED4611-199D-4B72-B46A-0C4D78B2D1A1
P2860
Immunologic mechanisms of EPO-associated pure red cell aplasia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Immunologic mechanisms of EPO-associated pure red cell aplasia.
@ast
Immunologic mechanisms of EPO-associated pure red cell aplasia.
@en
type
label
Immunologic mechanisms of EPO-associated pure red cell aplasia.
@ast
Immunologic mechanisms of EPO-associated pure red cell aplasia.
@en
prefLabel
Immunologic mechanisms of EPO-associated pure red cell aplasia.
@ast
Immunologic mechanisms of EPO-associated pure red cell aplasia.
@en
P1476
Immunologic mechanisms of EPO-associated pure red cell aplasia.
@en
P2093
Huub Schellekens
P304
P356
10.1016/J.BEHA.2005.01.016
P577
2005-01-01T00:00:00Z